Dynavax Technologies Corporation (DVAX)
USD 10.39
(-2.44%)
USD 10.39
(-2.44%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 106.63 Million USD | 90.4% |
| 2022 | 56 Million USD | 131.32% |
| 2021 | -178.8 Million USD | -196.25% |
| 2020 | 185.77 Million USD | 5.22% |
| 2019 | 176.56 Million USD | 242.69% |
| 2018 | 51.52 Million USD | 293.81% |
| 2017 | -26.58 Million USD | -9.45% |
| 2016 | -24.28 Million USD | 45.8% |
| 2015 | -44.81 Million USD | -12.16% |
| 2014 | -39.95 Million USD | -72.79% |
| 2013 | -23.12 Million USD | -204.28% |
| 2012 | -7.59 Million USD | 60.28% |
| 2011 | -19.13 Million USD | -79.28% |
| 2010 | -10.67 Million USD | 61.02% |
| 2009 | -27.37 Million USD | 2.58% |
| 2008 | -28.1 Million USD | -96.62% |
| 2007 | -14.29 Million USD | -0.98% |
| 2006 | -14.15 Million USD | -62.22% |
| 2005 | -8.72 Million USD | 47.41% |
| 2004 | -16.59 Million USD | 29.31% |
| 2003 | -23.46 Million USD | -353.84% |
| 2002 | -5.17 Million USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 124.06 Million USD | 16.35% |
| 2024 Q2 | 142.78 Million USD | 15.08% |
| 2023 Q3 | 98.58 Million USD | 217.95% |
| 2023 Q4 | 106.63 Million USD | 8.17% |
| 2023 Q2 | 31 Million USD | -61.07% |
| 2023 FY | 106.63 Million USD | 90.4% |
| 2023 Q1 | 79.63 Million USD | 42.19% |
| 2022 Q1 | 78.56 Million USD | 143.94% |
| 2022 Q3 | 59.23 Million USD | 584.41% |
| 2022 Q4 | 56 Million USD | -5.45% |
| 2022 Q2 | 8.65 Million USD | -88.98% |
| 2022 FY | 56 Million USD | 131.32% |
| 2021 Q2 | 126.73 Million USD | -8.15% |
| 2021 FY | -178.8 Million USD | -196.25% |
| 2021 Q1 | 137.98 Million USD | -25.72% |
| 2021 Q4 | -178.8 Million USD | -1629.56% |
| 2021 Q3 | 11.69 Million USD | -90.78% |
| 2020 Q1 | 181.6 Million USD | 2.86% |
| 2020 Q4 | 185.77 Million USD | 0.03% |
| 2020 Q2 | 158.44 Million USD | -12.75% |
| 2020 Q3 | 185.71 Million USD | 17.21% |
| 2020 FY | 185.77 Million USD | 5.22% |
| 2019 Q3 | 177.28 Million USD | 0.13% |
| 2019 FY | 176.56 Million USD | 242.69% |
| 2019 Q1 | 98.61 Million USD | 91.4% |
| 2019 Q2 | 177.05 Million USD | 79.54% |
| 2019 Q4 | 176.56 Million USD | -0.41% |
| 2018 Q4 | 51.52 Million USD | -16.37% |
| 2018 Q2 | 71.04 Million USD | 12.48% |
| 2018 Q1 | 63.16 Million USD | 337.61% |
| 2018 FY | 51.52 Million USD | 293.81% |
| 2018 Q3 | 61.6 Million USD | -13.28% |
| 2017 Q4 | -26.58 Million USD | -32.29% |
| 2017 Q3 | -20.09 Million USD | 46.66% |
| 2017 Q2 | -37.67 Million USD | -75.46% |
| 2017 Q1 | -21.47 Million USD | 11.6% |
| 2017 FY | -26.58 Million USD | -9.45% |
| 2016 Q1 | -38.85 Million USD | 13.29% |
| 2016 FY | -24.28 Million USD | 45.8% |
| 2016 Q2 | -24.78 Million USD | 36.21% |
| 2016 Q3 | -23.02 Million USD | 7.12% |
| 2016 Q4 | -24.28 Million USD | -5.51% |
| 2015 Q1 | -5.2 Million USD | 86.97% |
| 2015 Q4 | -44.81 Million USD | 56.51% |
| 2015 FY | -44.81 Million USD | -12.16% |
| 2015 Q3 | -103.03 Million USD | -281.22% |
| 2015 Q2 | -27.02 Million USD | -419.15% |
| 2014 Q3 | -19.65 Million USD | -15.41% |
| 2014 Q4 | -39.95 Million USD | -103.26% |
| 2014 FY | -39.95 Million USD | -72.79% |
| 2014 Q1 | -26.75 Million USD | -15.69% |
| 2014 Q2 | -17.03 Million USD | 36.33% |
| 2013 Q1 | -25.01 Million USD | -229.2% |
| 2013 Q3 | -12.19 Million USD | 30.67% |
| 2013 Q4 | -23.12 Million USD | -89.66% |
| 2013 FY | -23.12 Million USD | -204.28% |
| 2013 Q2 | -17.58 Million USD | 29.7% |
| 2012 Q2 | -20.62 Million USD | -222.47% |
| 2012 Q3 | -10.19 Million USD | 50.56% |
| 2012 Q4 | -7.59 Million USD | 25.49% |
| 2012 Q1 | -6.39 Million USD | 66.57% |
| 2012 FY | -7.59 Million USD | 60.28% |
| 2011 Q3 | -6.73 Million USD | 54.36% |
| 2011 FY | -19.13 Million USD | -79.28% |
| 2011 Q1 | -9.56 Million USD | 10.37% |
| 2011 Q2 | -14.74 Million USD | -54.17% |
| 2011 Q4 | -19.13 Million USD | -184.26% |
| 2010 FY | -10.67 Million USD | 61.02% |
| 2010 Q2 | -15.75 Million USD | 8.58% |
| 2010 Q1 | -17.23 Million USD | 37.07% |
| 2010 Q3 | -16.72 Million USD | -6.18% |
| 2010 Q4 | -10.67 Million USD | 36.2% |
| 2009 Q1 | -22.92 Million USD | 18.44% |
| 2009 FY | -27.37 Million USD | 2.58% |
| 2009 Q4 | -27.37 Million USD | -10.69% |
| 2009 Q3 | -24.73 Million USD | -4.11% |
| 2009 Q2 | -23.75 Million USD | -3.66% |
| 2008 FY | -28.1 Million USD | -96.62% |
| 2008 Q3 | -22.61 Million USD | -52.1% |
| 2008 Q4 | -28.1 Million USD | -24.25% |
| 2008 Q2 | -14.87 Million USD | 6.23% |
| 2008 Q1 | -15.85 Million USD | -10.95% |
| 2007 Q4 | -14.29 Million USD | 2.38% |
| 2007 FY | -14.29 Million USD | -0.98% |
| 2007 Q2 | -6.5 Million USD | 49.9% |
| 2007 Q1 | -12.97 Million USD | 8.3% |
| 2007 Q3 | -14.64 Million USD | -125.16% |
| 2006 Q1 | -16.84 Million USD | -93.03% |
| 2006 Q4 | -14.15 Million USD | 11.27% |
| 2006 FY | -14.15 Million USD | -62.22% |
| 2006 Q3 | -15.95 Million USD | -58.09% |
| 2006 Q2 | -10.09 Million USD | 40.09% |
| 2005 FY | -8.72 Million USD | 47.41% |
| 2005 Q4 | -8.72 Million USD | 54.48% |
| 2005 Q3 | -19.16 Million USD | -274.67% |
| 2005 Q2 | -5.11 Million USD | 55.13% |
| 2005 Q1 | -11.4 Million USD | 31.28% |
| 2004 Q1 | -75.01 Million USD | -219.64% |
| 2004 FY | -16.59 Million USD | 29.31% |
| 2004 Q2 | -73.95 Million USD | 1.4% |
| 2004 Q3 | -71.51 Million USD | 3.31% |
| 2004 Q4 | -16.59 Million USD | 76.8% |
| 2003 FY | -23.46 Million USD | -353.84% |
| 2003 Q4 | -23.46 Million USD | 0.0% |
| 2002 FY | -5.17 Million USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 75.505% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 1230.838% |
| Embecta Corp. | 1.31 Billion USD | 91.872% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 75.359% |
| PainReform Ltd. | -7.95 Million USD | 1441.321% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 782.043% |
| SCYNEXIS, Inc. | -19.35 Million USD | 651.085% |
| Journey Medical Corporation | -9.7 Million USD | 1198.311% |
| Safety Shot Inc | -2.28 Million USD | 4768.016% |
| Alpha Teknova, Inc. | 1.97 Million USD | -5301.976% |
| Bright Green Corporation | 1.84 Million USD | -5689.955% |
| Procaps Group, S.A. | 242.93 Million USD | 56.105% |
| Alvotech | 1.06 Billion USD | 89.981% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -13.192% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -42.275% |
| Cosmos Health Inc. | 8.59 Million USD | -1141.276% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 76.753% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 181.507% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 782.043% |
| Theratechnologies Inc. | 24.87 Million USD | -328.752% |
| Harrow Health, Inc. | 116.41 Million USD | 8.403% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 4331.548% |
| Biofrontera Inc. | 4.05 Million USD | -2529.068% |
| DURECT Corporation | -7.65 Million USD | 1493.193% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 418.057% |
| Cronos Group Inc. | -663.32 Million USD | 116.076% |
| OptiNose, Inc. | 58.06 Million USD | -83.648% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 82.894% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 831.78% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 2156.197% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -610.284% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 1776.744% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -99690.378% |
| Radius Health, Inc. | 359.28 Million USD | 70.32% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -53972.076% |
| ProPhase Labs, Inc. | 19.23 Million USD | -454.495% |
| Phibro Animal Health Corporation | 454.84 Million USD | 76.556% |
| Procaps Group S.A. | 242.93 Million USD | 56.105% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -2799.266% |
| Viatris Inc. | 17.13 Billion USD | 99.378% |
| Rockwell Medical, Inc. | 4.45 Million USD | -2293.066% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 2286.488% |
| SIGA Technologies, Inc. | -148.68 Million USD | 171.72% |
| Tilray Brands, Inc. | 158.97 Million USD | 32.924% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 12.521% |
| Shineco, Inc. | 29.29 Million USD | -264.062% |
| PetIQ, Inc. | 351.93 Million USD | 69.7% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 3775.259% |
| Incannex Healthcare Limited | -5.48 Million USD | 2044.12% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 39.856% |
| Alimera Sciences, Inc. | 55.3 Million USD | -92.799% |
| Silver Spike Investment Corp. | -32.61 Million USD | 426.985% |
| Assertio Holdings, Inc. | -32.52 Million USD | 427.815% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 7262.855% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 2207.251% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 2315.102% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1398.293% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -2428.693% |
| Hempacco Co., Inc. | 13.61 Million USD | -683.235% |
| Talphera, Inc. | -5.72 Million USD | 1963.922% |
| Alvotech | 1.06 Billion USD | 89.981% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -1392.442% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 210.263% |
| Currenc Group, Inc. | -16.57 Million USD | 743.421% |
| Kamada Ltd. | -46.43 Million USD | 329.661% |
| Indivior PLC | -33.95 Million USD | 414.076% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -40823.116% |
| Flora Growth Corp. | -713 Thousand USD | 15055.82% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1398.293% |
| Evolus, Inc. | 63.7 Million USD | -67.381% |
| HUTCHMED (China) Limited | -197.45 Million USD | 154.004% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 77.743% |
| Akanda Corp. | 3.9 Million USD | -2630.789% |